Cost-effectiveness of human papillomavirus vaccination among girls aged 9–16 years in China: a meta-analysis
Introduction Imported 2 v, 4 v, and 9vHPV vaccines are costly in China, whereas the domestic 2vHPV is more affordable. This study aimed to summarize cost-effectiveness evidence by pooling the incremental net monetary benefit (INB) of HPV vaccination for girls in China.Methods We searched PubMed, Emb...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2025.2517715 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850223340519686144 |
|---|---|
| author | Xiaoya Fu Yilan Xia Weiyu Zhou Yihan Lu |
| author_facet | Xiaoya Fu Yilan Xia Weiyu Zhou Yihan Lu |
| author_sort | Xiaoya Fu |
| collection | DOAJ |
| description | Introduction Imported 2 v, 4 v, and 9vHPV vaccines are costly in China, whereas the domestic 2vHPV is more affordable. This study aimed to summarize cost-effectiveness evidence by pooling the incremental net monetary benefit (INB) of HPV vaccination for girls in China.Methods We searched PubMed, Embase®, Web of Science, and Cochrane databases from inception to 18 January 2024, for cost-effectiveness analyses of 2vHPV, 4vHPV, and 9vHPV vaccines compared to no HPV vaccination (NoV) and to each other. All monetary units were adjusted to 2022 US dollars. INBs were calculated as the difference in incremental effectiveness multiplied by the willingness-to-pay threshold minus the incremental cost and pooled by vaccine type using random-effects or fixed-effects models.Results Sixteen studies involving 61 comparisons were included. The INBs (95% CI) for domestic 2vHPV, imported 2vHPV, 4vHPV, and 9vHPV vaccines, compared to NoV, were USD 569.99 (58.62, 1081.36), 186.39 (86.21, 286.57), 239.14 (142.46, 335.81), and 298.41 (198.31, 398.51), respectively. HPV vaccines were significantly cost-effective compared to NoV. 4vHPV vaccine was less cost-effective than imported 2vHPV vaccine, with an INB of USD − 693.98 (−1062.17, −325.79).Conclusions HPV vaccines were cost-effective compared to NoV in China. Our findings would facilitate policy-making of HPV immunization programs. |
| format | Article |
| id | doaj-art-ee331a4f7b4641688b5ab16ba39e89b6 |
| institution | OA Journals |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-ee331a4f7b4641688b5ab16ba39e89b62025-08-20T02:05:59ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952025-12-0124152453410.1080/14760584.2025.2517715Cost-effectiveness of human papillomavirus vaccination among girls aged 9–16 years in China: a meta-analysisXiaoya Fu0Yilan Xia1Weiyu Zhou2Yihan Lu3Department of Epidemiology, Ministry of Education Key Laboratory of Public Health Safety, School of Public Health, Fudan University, Shanghai, ChinaDepartment of Epidemiology, Ministry of Education Key Laboratory of Public Health Safety, School of Public Health, Fudan University, Shanghai, ChinaDepartment of Epidemiology, Ministry of Education Key Laboratory of Public Health Safety, School of Public Health, Fudan University, Shanghai, ChinaDepartment of Epidemiology, Ministry of Education Key Laboratory of Public Health Safety, School of Public Health, Fudan University, Shanghai, ChinaIntroduction Imported 2 v, 4 v, and 9vHPV vaccines are costly in China, whereas the domestic 2vHPV is more affordable. This study aimed to summarize cost-effectiveness evidence by pooling the incremental net monetary benefit (INB) of HPV vaccination for girls in China.Methods We searched PubMed, Embase®, Web of Science, and Cochrane databases from inception to 18 January 2024, for cost-effectiveness analyses of 2vHPV, 4vHPV, and 9vHPV vaccines compared to no HPV vaccination (NoV) and to each other. All monetary units were adjusted to 2022 US dollars. INBs were calculated as the difference in incremental effectiveness multiplied by the willingness-to-pay threshold minus the incremental cost and pooled by vaccine type using random-effects or fixed-effects models.Results Sixteen studies involving 61 comparisons were included. The INBs (95% CI) for domestic 2vHPV, imported 2vHPV, 4vHPV, and 9vHPV vaccines, compared to NoV, were USD 569.99 (58.62, 1081.36), 186.39 (86.21, 286.57), 239.14 (142.46, 335.81), and 298.41 (198.31, 398.51), respectively. HPV vaccines were significantly cost-effective compared to NoV. 4vHPV vaccine was less cost-effective than imported 2vHPV vaccine, with an INB of USD − 693.98 (−1062.17, −325.79).Conclusions HPV vaccines were cost-effective compared to NoV in China. Our findings would facilitate policy-making of HPV immunization programs.https://www.tandfonline.com/doi/10.1080/14760584.2025.2517715Cost-effectiveness analysishuman papillomavirus vaccineincremental net benefitmeta-analysiseconomic evaluation |
| spellingShingle | Xiaoya Fu Yilan Xia Weiyu Zhou Yihan Lu Cost-effectiveness of human papillomavirus vaccination among girls aged 9–16 years in China: a meta-analysis Expert Review of Vaccines Cost-effectiveness analysis human papillomavirus vaccine incremental net benefit meta-analysis economic evaluation |
| title | Cost-effectiveness of human papillomavirus vaccination among girls aged 9–16 years in China: a meta-analysis |
| title_full | Cost-effectiveness of human papillomavirus vaccination among girls aged 9–16 years in China: a meta-analysis |
| title_fullStr | Cost-effectiveness of human papillomavirus vaccination among girls aged 9–16 years in China: a meta-analysis |
| title_full_unstemmed | Cost-effectiveness of human papillomavirus vaccination among girls aged 9–16 years in China: a meta-analysis |
| title_short | Cost-effectiveness of human papillomavirus vaccination among girls aged 9–16 years in China: a meta-analysis |
| title_sort | cost effectiveness of human papillomavirus vaccination among girls aged 9 16 years in china a meta analysis |
| topic | Cost-effectiveness analysis human papillomavirus vaccine incremental net benefit meta-analysis economic evaluation |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2025.2517715 |
| work_keys_str_mv | AT xiaoyafu costeffectivenessofhumanpapillomavirusvaccinationamonggirlsaged916yearsinchinaametaanalysis AT yilanxia costeffectivenessofhumanpapillomavirusvaccinationamonggirlsaged916yearsinchinaametaanalysis AT weiyuzhou costeffectivenessofhumanpapillomavirusvaccinationamonggirlsaged916yearsinchinaametaanalysis AT yihanlu costeffectivenessofhumanpapillomavirusvaccinationamonggirlsaged916yearsinchinaametaanalysis |